Q: What is Bristol Myers Squibb’s approach to dermatology research?
Mary Beth: At Bristol Myers Squibb, we’re committed to discovering, developing and delivering innovative medicines that help patients prevail over serious illnesses, including a variety of diseases in dermatology. Our deep understanding of the science behind modulating the body’s immune response to treat disease – pioneered over 20 years ago – set in motion our pursuit of pathbreaking science for diseases such as psoriasis and atopic dermatitis, as well as other serious dermatologic conditions that we are in the early stages of investigating.
Q: What unmet needs are driving Bristol Myers Squibb’s clinical research in dermatology?
Mary Beth: For the millions of people worldwide living with immune-mediated dermatologic diseases, their conditions are more than skin deep. Even with expanded treatment options available, many people still struggle with inadequate disease control, often going untreated or undertreated, and are in need of additional effective and well-tolerated therapies.
For example, while there may be a perception that psoriasis is only a skin disease, it is actually a chronic immune-mediated disease that is associated with multiple comorbidities including psoriatic arthritis, cardiovascular disease, metabolic syndrome, obesity, diabetes, inflammatory bowel disease and others. For psoriasis specifically, the pain, itching, bleeding and skin tightness can take both a physical and emotional toll that makes everyday life more challenging.
Though we’ve made significant strides in research, important work still remains to understand the cause of the various immune-mediated diseases that we are studying, and this understanding will help us determine if select therapies are impacting the pathogenesis of the disease. Every clinical trial is an opportunity to improve our understanding of these diseases and closely assess the data to discover insights that move the field forward.